Large animal models of cardiovascular disease

Cell Biochemistry and Function

Volumn 34, Issue 3, 2016, Pages 113-132

  Tsang, H G ^a   Rashdan, N A ^a   Whitelaw, C B A ^a   Corcoran, B M ^b   Summers, K M ^a   MacRae, V E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Aortic stenosis; Calcific aortic valve disease; Cardiovascular disease; Genetic engineering; Large animal models; Marfan syndrome; Vascular calcification

Indexed keywords

ABDOMINAL AORTA ANEURYSM; ANIMAL MODEL; AORTA VALVE DISEASE; AORTIC DYSFUNCTION; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CALCIFIC AORTIC VALVE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR DYSFUNCTION; CHEMICAL COMPOSITION; DIABETES MELLITUS; EXTRACELLULAR MATRIX; ISCHEMIC HEART DISEASE; MARFAN SYNDROME; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC ANIMAL; VALVULAR HEART DISEASE; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HUMANS;

EID: 84959431629     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.3173     Document Type: Article

References (292)

1. Solomon EP, Berg LR, Martin DW. Biology. Thomson-Brooks/Cole, London: Belmont, Calif., 2008.
2. Ross MH, Pawlina W. Histology: A Text and Atlas: With Correlated Cell and Molecular Biology. Lippincott Williams & Wilkins: Philadelphia, Pa.; London, 2011.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128. doi:10.1016/S0140-6736(12)61728-0.
4. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics-2014 update a report from the American Heart Association. Circulation 2014; 129: 399-410. doi:10.1161/01.cir.0000442015.53336.12.
5. WHO. World Health Statistics 2014. World Health Organization: Geneva, 2014.
6. Suzuki Y, Yeung AC, Ikeno F. The pre-clinical animal model in the translational research of interventional cardiology. JACC Cardiovasc Interv 2009; 2: 373-383. doi:10.1016/j.jcin.2009.03.004.
7. Walters EM, Wolf E, Whyte JJ, et al. Completion of the swine genome will simplify the production of swine as a large animal biomedical model. BMC Med Genomics 2012; 5: 55. doi:10.1186/1755-8794-5-55.
8. Chorro FJ, Such-Belenguer L, López-Merino V. Animal models of cardiovascular disease. Rev Esp Cardiol 2009; 62: 69-84.
9. Dixon JA, Spinale FG. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail 2009; 2: 262-271. doi:10.1161/CIRCHEARTFAILURE.108.814459.
10. Munford RS. Murine responses to endotoxin: another dirty little secret? J Infect Dis 2010; 201: 175-177. doi:10.1086/649558.
11. Warren HS, Fitting C, Hoff E, et al. Resilience to bacterial infection: difference between species could be due to proteins in serum. J Infect Dis 2010; 201: 223-232. doi:10.1086/649557.
12. Doeing DC, Borowicz JL, Crockett ET. Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin Pathol 2003; 3: 3. doi:10.1186/1472-6890-3-3.
13. Meurens F, Summerfield A, Nauwynck H, et al. The pig: a model for human infectious diseases. Trends Microbiol 2012; 20: 50-57. doi:10.1016/j.tim.2011.11.002.
14. Dumonde DC, Pulley MS, Paradinas FJ, et al. Histological features of skin reactions to human lymphoid cell line lymphokine in patients with advanced cancer. J Pathol 1982; 138: 289-308. doi:10.1002/path.1711380402.
15. Crowle AJ. 1975. Delayed hypersensitivity in the mouse. In Advances in Immunology, Dixon FJ, Henry GK (eds.). Academic Press: London, 197-264.
16. Vilahur G, Padro T, Badimon L. Atherosclerosis and thrombosis: insights from large animal models. BioMed Res Intern 2011; 2011.
17. Lunney JK. Advances in swine biomedical model genomics. Int J Biol Sci 2007; 3: 179-184.
18. Maganti K, Rigolin VH, Sarano ME, et al. Valvular heart disease: diagnosis and management. Mayo Clin Proc 2010; 85: 483-500. doi:10.4065/mcp.2009.0706.
19. Kaniewska E, Sielicka A, Sarathchandra P, et al. Immunohistochemical and functional analysis of ectonucleoside triphosphate diphosphohydrolase 1 (cd39) and ecto-5'-nucleotidase (cd73) in pig aortic valves. Nucleosides Nucleotides Nucleic Acids 2014; 33: 305-312. doi:10.1080/15257770.2014.885985.
20. Schoen FJ. Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation 2008; 118: 1864-1880. doi:10.1161/CIRCULATIONAHA.108.805911.
21. Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation 2011; 124: 1783-1791. doi:10.1161/CIRCULATIONAHA.110.006767.
22. Leopold JA. Cellular mechanisms of aortic valve calcification. Circ Cardiovasc Interv 2012; 5: 605-614. doi:10.1161/CIRCINTERVENTIONS.112.971028.
23. Butcher JT, Mahler GJ, Hockaday LA. Aortic valve disease and treatment: the need for naturally engineered solutions. Adv Drug Deliv Rev 2011; 63: 242-268. doi:10.1016/j.addr.2011.01.008.
24. Balaoing LR, Post AD, Liu H, et al. Age-related changes in aortic valve hemostatic protein regulation. Arterioscler Thromb Vasc Biol 2014; 34: 72-80. doi:10.1161/atvbaha.113.301936.
25. Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 2011; 209: 139-151. doi:10.1530/JOE-10-0377.
26. Davis MR, Summers KM. Structure and function of the mammalian fibrillin gene family: implications for human connective tissue diseases. Mol Genet Metab 2012; 107: 635-647. doi:10.1016/j.ymgme.2012.07.023.
27. Ramirez F, Pereira L. Mutations of extracellular matrix components in vascular disease. Ann Thorac Surg 1999; 67: 1857-1858; discussion 1868-1870. DOI: S0003497599004373 [pii]
28. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111: 3316-3326. doi:10.1161/CIRCULATIONAHA.104.486738.
29. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24: 1231-1243.
30. Cowell SJ, Newby DE, Boon NA, et al. Calcific aortic stenosis: same old story? Age Ageing 2004; 33: 538-544. doi:10.1093/ageing/afh175.
31. Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999; 341: 142-147. doi:10.1056/NEJM199907153410302.
32. Ortlepp JR, Schmitz F, Bozoglu T, et al. Cardiovascular risk factors in patients with aortic stenosis predict prevalence of coronary artery disease but not of aortic stenosis: an angiographic pair matched case-control study. Heart 2003; 89: 1019-1022.
33. Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90: 844-853.
34. Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995; 76: 928-932.
35. Bach DS, Siao D, Girard SE, et al. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk. Circ Cardiovasc Qual Outcomes 2009; 2: 533-539. doi:10.1161/CIRCOUTCOMES.109.848259.
36. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res 2011; 108: 1392-1412. doi:10.1161/CIRCRESAHA.110.234138.
37. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007; 9(Suppl 1): S1. doi:10.1186/ar2165.
38. Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005; 437: 270-274. doi:10.1038/nature03940.
39. Chen JH, Simmons CA. Cell-matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues. Circ Res 2011; 108: 1510-1524. doi:10.1161/CIRCRESAHA.110.234237.
40. Yao Y, Bennett BJ, Wang X, et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res 2010; 107: 485-494. doi:10.1161/CIRCRESAHA.110.219071.
41. Koos R, Krueger T, Westenfeld R, et al. Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 2009; 101: 706-713.
42. Schinke T, Amendt C, Trindl A, et al. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996; 271: 20789-20796.
43. Avila-Díaz M, Mora-Villalpando C, Prado-Uribe MC, et al. De novo development of heart valve calcification in incident peritoneal dialysis patients. Arch Med Res 2013; 44: 638-644. doi:10.1016/j.arcmed.2013.10.015.
44. Ix JH, Chertow GM, Shlipak MG, et al. Association of fetuin-a with mitral annular calcification and aortic stenosis among persons with coronary heart disease data from the heart and soul study. Circulation 2007; 115: 2533-2539.
45. Yu PJ, Skolnick A, Ferrari G, et al. Correlation between plasma osteopontin levels and aortic valve calcification: potential insights into the pathogenesis of aortic valve calcification and stenosis. J Thorac Cardiovasc Surg 2009; 138: 196-199. doi:10.1016/j.jtcvs.2008.10.045.
46. Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003; 107: 2181-2184. doi:10.1161/01.CIR.0000070591.21548.69.
47. Caira FC, Stock SR, Gleason TG, et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006; 47: 1707-1712. doi:10.1016/j.jacc.2006.02.040.
48. Karsenty G, Ducy P, Starbuck M, et al. Cbfa1 as a regulator of osteoblast differentiation and function. Bone 1999; 25: 107-108.
49. Gehron Robey P, Boskey AL. The biochemistry of bone. In Osteoporosis, Marcus R, Feldman D (eds.). Raven Press: New York; 1996, 95-184.
50. Mohler ER, Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. Circulation 2001; 103: 1522-1528.
51. Shimizu T, Tanaka T, Iso T, et al. Notch signaling pathway enhances bone morphogenetic protein 2 (BMP2) responsiveness of Msx2 gene to induce osteogenic differentiation and mineralization of vascular smooth muscle cells. J Biol Chem 2011; 286: 19138-19148. doi:10.1074/jbc.M110.175786.
52. White MP, Theodoris CV, Liu L, et al. NOTCH1 regulates matrix gla protein and calcification gene networks in human valve endothelium. J Mol Cell Cardiol 2015; 84: 13-23. doi:10.1016/j.yjmcc.2015.04.006.
53. Aikawa E, Otto CM. Look more closely at the valve imaging calcific aortic valve disease. Circulation 2012; 125: 9-11. doi:10.1161/circulationaha.111.073452.
54. O'Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996; 16: 523-532.
55. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999; 19: 1218-1222.
56. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17: 680-687.
57. Mazzone A, Epistolato MC, De Caterina R, et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol 2004; 43: 1670-1676. doi:10.1016/j.jacc.2003.12.041.
58. Akahori H, Tsujino T, Naito Y, et al. Intraleaflet haemorrhage is associated with rapid progression of degenerative aortic valve stenosis. Eur Heart J 2011; 32: 888-896. doi:10.1093/eurheartj/ehq479.
59. Butcher JT, Penrod AM, Garcia AJ, et al. Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments. Arterioscler Thromb Vasc Biol 2004; 24: 1429-1434. doi:10.1161/01.ATV.0000130462.50769.5a.
60. Butcher JT, Nerem RM. Porcine aortic valve interstitial cells in three-dimensional culture: comparison of phenotype with aortic smooth muscle cells. J Heart Valve Dis 2004; 13: 478-485.
61. Sider KL, Zhu C, Kwong AV, et al. Evaluation of a porcine model of early aortic valve sclerosis. Cardiovasc Pathol 2014; 23: 289-297. doi:10.1016/j.carpath.2014.05.004.
62. Mohler ER, Chawla MK, Chang AW, et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 1999; 8: 254-260.
63. Moghadasian MH, Frohlich JJ, McManus BM. Advances in experimental dyslipidemia and atherosclerosis. Lab Invest 2001a; 81: 1173-1183. doi:10.1038/labinvest.3780331.
64. Moghadasian MH. Experimental atherosclerosis-a historical overview. Life Sci 2002; 70: 855-865. doi:10.1016/s0024-3205(01)01479-5.
65. Guerraty M, Mohler ER, III. Models of aortic valve calcification. J Invest Med 2007; 55: 278-283. doi:10.2310/6650.2007.00012.
66. Sider KL, Blaser MC, Simmons CA. Animal models of calcific aortic valve disease. Int J Inflam 2011; (2011364310). doi:10.4061/2011/364310.
67. Johnson CM, Fass DN. Porcine cardiac valvular endothelial cells in culture. A relative deficiency of fibronectin synthesis in vitro. Lab Invest 1983; 49: 589-598.
68. Manduteanu I, Popov D, Radu A, et al. Calf cardiac valvular endothelial cells in culture: production of glycosaminoglycans, prostacyclin and fibronectin. J Mol Cell Cardiol 1988; 20: 103-118.
69. Paranya G, Vineberg S, Dvorin E, et al. Aortic valve endothelial cells undergo transforming growth factor-beta-mediated and non-transforming growth factor-beta-mediated transdifferentiation in vitro. Am J Pathol 2001; 159: 1335-1343.
70. Messier RH, Bass BL, Aly HM, et al. Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. J Surg Res 1994; 57: 1-21. doi:10.1006/jsre.1994.1102.
71. Johnson CM, Hanson MN, Helgeson SC. Porcine cardiac valvular subendothelial cells in culture: cell isolation and growth characteristics. J Mol Cell Cardiol 1987; 19: 1185-1193.
72. Yperman J, De Visscher G, Holvoet P, et al. Molecular and functional characterization of ovine cardiac valve-derived interstitial cells in primary isolates and cultures. Tissue Eng 2004; 10: 1368-1375. doi:10.1089/ten.2004.10.1368.
73. Butcher JT, Nerem RM. Valvular endothelial cells regulate the phenotype of interstitial cells in co-culture: effects of steady shear stress. Tissue Eng 2006; 12: 905-915. doi:10.1089/ten.2006.12.905.
74. Cuniberti LA, Stutzbach PG, Guevara E, et al. Development of mild aortic valve stenosis in a rabbit model of hypertension. J Am Coll Cardiol 2006; 47: 2303-2309. doi:10.1016/j.jacc.2005.12.070.
75. Skold BH, Getty R, Ramsey FK. Spontaneous atherosclerosis in the arterial system of aging swine. Am J Vet Res 1966; 27: 257-273.
76. Dixon JL, Stoops JD, Parker JL, et al. Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. Arterioscler Thromb Vasc Biol 1999; 19: 2981-2992.
77. Gerrity RG, Natarajan R, Nadler JL, et al. Diabetes-induced accelerated atherosclerosis in swine. Diabetes 2001; 50: 1654-1665.
78. Simmons CA, Grant GR, Manduchi E, et al. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res 2005; 96: 792-799. doi:10.1161/01.RES.0000161998.92009.64.
79. Viaene L, Behets GJ, Claes K, et al. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 2013. doi:10.1093/ndt/gft039.
80. Warnock JN, Nanduri B, Pregonero Gamez CA, et al. Gene profiling of aortic valve interstitial cells under elevated pressure conditions: modulation of inflammatory gene networks. Int J Inflam 2011; 2011: 176412. DOI: 10.4061/2011/176412
81. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352: 2389-2397. doi:10.1056/NEJMoa043876.
82. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-1356. doi:10.1056/NEJMoa0804602.
83. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010; 121: 306-314. doi:10.1161/CIRCULATIONAHA.109.900027.
84. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964. doi:10.1097/01.ASN.0000145894.57533.C4.
85. Li XW, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-912. doi:10.1161/01.RES.0000216409.20863.e7.
86. Zhu D, Mackenzie NC, Farquharson C, et al. Mechanisms and clinical consequences of vascular calcification. Front Endocrinol (Lausanne) 2012; 3: 95. doi:10.3389/fendo.2012.00095.
87. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24: 1161-1170. doi:10.1161/01.ATV.0000133194.94939.42.
88. Towler DA. Vascular calcification: a perspective on an imminent disease epidemic. IBMS BoneKEy 2008; 5: 41-58. doi:10.1138/20080298.
89. Oliveira RB, Okazaki H, Stinghen AE, et al. Vascular calcification in chronic kidney disease: a review. J Bras Nefrol 2013; 35: 147-161. doi:10.5935/0101-2800.20130024.
90. Chen NX, Duan D, O'Neill KD, et al. High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrol Dial Transplant 2006; 21: 3435-3442. doi:10.1093/ndt/gfl429.
91. Mackenzie NC, Zhu D, Milne EM, et al. Altered bone development and an increase in FGF-23 expression in Enpp1(-/-) mice. PLoS One 2012a; 7 e32177. doi:10.1371/journal.pone.0032177.
92. London GM, Guérin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
93. McNally EM. Genetics of vascular calcification. Circ Res 2011; 109: 248-249. doi:10.1161/RES.0b013e31822a19fe.
94. Speer MY, Giachelli CM. Regulation of cardiovascular calcification. Cardiovasc Pathol 2004; 13: 63-70. doi:10.1016/S1054-8807(03)00130-3.
95. Shroff RC, Shanahan CM. The vascular biology of calcification. Semin Dialysis 2007; 20: 103-109. doi:10.1111/j.1525-139X.2007.00255.x.
96. Demer LL, Tintut Y. Vascular calcification-pathobiology of a multifaceted disease. Circulation 2008; 117: 2938-2948. doi:10.1161/circulationaha.107.743161.
97. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496.
98. Frink RJ. Inflammatory Atherosclerosis: Characteristics of the Injurious Agent. Heart Research Foundation: Sacramento, Calif., 2002.
99. Kim KM. Calcification of matrix vesicles in human aortic valve and aortic media. Fed Proc 1976; 35: 156-162.
100. Tanimura A, McGregor DH, Anderson HC. Calcification in atherosclerosis. I. Human studies. J Exp Pathol 1986; 2: 261-273.
101. Boström K, Watson KE, Horn S, et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-1809. doi:10.1172/JCI116391.
102. Fitzpatrick LA, Severson A, Edwards WD, et al. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 1994; 94: 1597-1604. doi:10.1172/JCI117501.
103. Giachelli CM, Bae N, Almeida M, et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993; 92: 1686-1696. doi:10.1172/JCI116755.
104. Hirota S, Imakita M, Kohri K, et al. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 1993; 143: 1003-1008.
105. Shanahan CM, Cary NR, Metcalfe JC, et al. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994; 93: 2393-2402. doi:10.1172/JCI117246.
106. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1998-2003.
107. de Kreutzenberg SV, Fadini GP, Guzzinati S, et al. Carotid plaque calcification predicts future cardiovascular events in type 2 diabetes. Diabetes Care 2015; 38: 1937-1944.
108. Vengrenyuk Y, Carlier S, Xanthos S, et al. A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc Natl Acad Sci U S A 2006; 103: 14678-14683. doi:10.1073/pnas.0606310103.
109. Bluestein D, Alemu Y, Avrahami I, et al. Influence of microcalcifications on vulnerable plaque mechanics using FSI modeling. J Biomech 2008; 41: 1111-1118. doi:10.1016/j.jbiomech.2007.11.029.
110. Wenk JF, Papadopoulos P, Zohdi TI. Numerical modeling of stress in stenotic arteries with microcalcifications: a micromechanical approximation. J Biomech Eng 2010; 132 091011. doi:10.1115/1.4001351.
111. Cheng GC, Loree HM, Kamm RD, et al. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation 1993; 87: 1179-1187.
112. Huang H, Virmani R, Younis H, et al. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation 2001; 103: 1051-1056.
113. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293-2299. doi:10.1111/j.1523-1755.2004.66015.x.
114. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-897. doi:10.1038/ki.2008.644.
115. Zhu D, Mackenzie NC, Millán JL, et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011; 6 e19595. doi:10.1371/journal.pone.0019595.
116. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154.
117. Speer MY, Yang HY, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104: 733-741. doi:10.1161/CIRCRESAHA.108.183053.
118. Rutsch F, Nitschke Y, Terkeltaub R. Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. Circ Res 2011; 109: 578-592. doi:10.1161/CIRCRESAHA.111.247965.
119. Schäfer C, Heiss A, Schwarz A, et al. The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366.
120. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
121. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268.
122. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-1407. doi:10.1161/01.atv.18.9.1400.
123. Sancho J, Duh Q, Oms L, et al. A new experimental model for secondary hyperparathyroidism. Surgery 1989; 106: 1002-1008.
124. Vercauteren SR, Ysebaert DK, De Greef KE, et al. Chronic reduction in renal mass in the rat attenuates ischemia/reperfusion injury and does not impair tubular regeneration. J Am Soc Nephrol 1999; 10: 2551-2561.
125. Koleganova N, Piecha G, Ritz E, et al. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 2009; 75: 60-71.
126. Mizobuchi M, Ogata H, Hatamura I, et al. Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. Nephrol Dial Transplant 2006; 21: 911-916. doi:10.1093/ndt/gfk008.
127. Mizobuchi M, Finch J, Martin D, et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715.
128. Lopez I, Mendoza F, Aguilera-Tejero E, et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307.
129. Haffner D, Hocher B, Müller D, et al. Systemic cardiovascular disease in uremic rats induced by 1, 25 (OH) 2D3. J Hypertens 2005; 23: 1067-1075.
130. Yokozawa T, Zheng PD, Oura H, et al. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986; 44: 230-234.
131. Katsumata K, Kusano K, Hirata M, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003; 64: 441-450.
132. Rutsch F, Ruf N, Vaingankar S, et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003; 34: 379-381. doi:10.1038/ng1221.
133. Levy-Litan V, Hershkovitz E, Avizov L, et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 2010; 86: 273-278. doi:10.1016/j.ajhg.2010.01.010.
134. Lorenz-Depiereux B, Schnabel D, Tiosano D, et al. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010; 86: 267-272. doi:10.1016/j.ajhg.2010.01.006.
135. Nitschke Y, Baujat G, Botschen U, et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet 2012; 90: 25-39. doi:10.1016/j.ajhg.2011.11.020.
136. Rutsch F, Vaingankar S, Johnson K, et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 2001; 158: 543-554. doi:10.1016/S0002-9440(10)63996-X.
137. Mackenzie NC, Huesa C, Rutsch F, et al. New insights into NPP1 function: lessons from clinical and animal studies. Bone 2012b; 51: 961-968. doi:10.1016/j.bone.2012.07.014.
138. Cranley JJ. Focal medial calcification of the pulmonary artery: a survey of 1066 horses. Equine Vet J 1983; 15: 278-280.
139. Imaizumi K, Nakamura T, Kiryu K, et al. Morphological changes of the aorta and pulmonary artery in thoroughbred racehorses. J Comp Pathol 1989; 101: 1-9.
140. Nakamura T, Kiryu K, Machida N, et al. Histologic features of the carotid artery trifurcation in thoroughbreds. Am J Vet Res 1992; 53: 288-290.
141. Arroyo LG, Hayes MA, Delay J, et al. Arterial calcification in race horses. Vet Pathol 2008; 45: 617-625. doi:10.1354/vp.45-5-617.
142. Huesa C, Staines KA, Millan L, et al. Effects of etidronate on the Enpp1(-/-) mouse model of generalized arterial calcification of infancy. Int J Mol Med 2015; 36: 159-165. doi:10.3892/ijmm.2015.2212.
143. Russell RG. Bisphosphonates: the first 40years. Bone 2011; 49: 2-19. doi:10.1016/j.bone.2011.04.022.
144. Otero JE, Gottesman GS, McAlister WH, et al. Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy. J Bone Miner Res 2013; 28: 419-430. doi:10.1002/jbmr.1752.
145. Albright RA, Stabach P, Cao W, et al. ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy. Nat Commun 2015; 6 10006. doi:10.1038/ncomms10006.
146. Bunton TE, Biery NJ, Myers L, et al. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res 2001; 88: 37-43.
147. Sakai LY, Keene DR, Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol 1986; 103: 2499-2509.
148. Quondamatteo F, Reinhardt DP, Charbonneau NL, et al. Fibrillin-1 and fibrillin-2 in human embryonic and early fetal development. Matrix Biol 2002; 21: 637-646.
149. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation 2005; 111: e150-e157. doi:10.1161/01.CIR.0000155243.70456.F4.
150. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013; 34: 3491-3500. doi:10.1093/eurheartj/eht334.
151. Potter KA, Besser TE. Cardiovascular lesions in bovine Marfan syndrome. Vet Pathol 1994; 31: 501-509.
152. Besser TE, Potter KA, Bryan GM, et al. An animal model of the Marfan syndrome. Am J Med Genet 1990; 37: 159-165. doi:10.1002/ajmg.1320370137.
153. Singleton AC, Mitchell AL, Byers PH, et al. Bovine model of Marfan syndrome results from an amino acid change (c.3598G>A, p.E1200K) in a calcium-binding epidermal growth factor-like domain of fibrillin-1. Hum Mutat 2005; 25: 348-352. doi:10.1002/humu.20152.
154. Potter KA, Hoffman Y, Sakai LY, et al. Abnormal fibrillin metabolism in bovine Marfan syndrome. Am J Pathol 1993; 142: 803-810.
155. Hirano T, Matsuhashi T, Kobayashi N, et al. Identification of an FBN1 mutation in bovine Marfan syndrome-like disease. Anim Genet 2012; 43: 11-17. doi:10.1111/j.1365-2052.2011.02209.x.
156. Rezg R, Barreto FC, Barreto DV, et al. Inhibitors of vascular calcification as potential therapeutic targets. J Nephrol 2011; 24: 416-427. doi:10.5301/JN.2011.8420.
157. Pereira L, Andrikopoulos K, Tian J, et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 1997; 17: 218-222. doi:10.1038/ng1097-218.
158. Sugitani H, Wachi H, Mecham RP, et al. Accelerated calcification represses the expression of elastic fiber components and lysyl oxidase in cultured bovine aortic smooth muscle cells. J Atheroscler Thromb 2002; 9: 292-298.
159. Larson EW, Edwards WD. Risk factors for aortic dissection: a necropsy study of 161 cases. Am J Cardiol 1984; 53: 849-855.
160. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005; 111: 920-925. doi:10.1161/01.CIR.0000155623.48408.C5.
161. Mohamed SA, Aherrahrou Z, Liptau H, et al. Novel missense mutations (p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve. Biochem Biophys Res Commun 2006; 345: 1460-1465. doi:10.1016/j.bbrc.2006.05.046.
162. McKellar SH, Tester DJ, Yagubyan M, et al. Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2007; 134: 290-296. doi:10.1016/j.jtcvs.2007.02.041.
163. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol 2010; 55: 2789-2800. doi:10.1016/j.jacc.2009.12.068.
164. Laforest B, Nemer M. Genetic insights into bicuspid aortic valve formation. Cardiol Res Pract 2012; 2012: 180297. DOI: 10.1155/2012/180297
165. Nataatmadja M, West M, West J, et al. Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation 2003; 108(Suppl 1): II329-II334. doi:10.1161/01.cir.0000087660.82721.15.
166. Getz GS, Reardon CA. Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 1104-1115. doi:10.1161/atvbaha.111.237693.
167. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126. doi:10.1056/NEJM199901143400207.
168. Hines TG, Jacobson NL, Beitz DC, et al. Dietary calcium and vitamin D: risk factors in the development of atherosclerosis in young goats. J Nutr 1985; 115: 167-178.
169. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. Elsevier Health Sciences: Philadelphia, Pa., 2012.
170. Hall JE. Guyton and Hall Textbook of Medical Physiology. Elsevier Health Sciences, 2015.
171. Davies PF, Remuzzi A, Gordon EJ, et al. Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro. Proc Natl Acad Sci U S A 1986; 83: 2114-2117.
172. Back M, Bu DX, Branstrom R, et al. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. ProcNatlAcadSciUSA 2005; 102: 17501-17506.
173. Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study. Ann Intern Med 1971; 74: 1-12.
174. Rosengren A, Eriksson H, Larsson B, et al. Secular changes in cardiovascular risk factors over 30years in Swedish men aged 50: the study of men born in 1913, 1923, 1933 and 1943. J Intern Med 2000; 247: 111-118.
175. Daida H, Teramoto T, Kitagawa Y, et al. The relationship between low-density lipoprotein cholesterol levels and the incidence of cardiovascular disease in high-risk patients treated with pravastatin: main results of the APPROACH-J study. Int Heart J 2014; 55: 39-47.
176. Kapourchali FR, Surendiran G, Chen L, et al. Animal models of atherosclerosis. World J Clin Cases: WJCC 2014; 2: 126-132. DOI: 10.12998/wjcc.v2.i5.126
177. Barter PJ, Brewer HB, Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 160-167.
178. Mahley R. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630. doi:10.1126/science.3283935.
179. Breslow JL, Zannis VI, SanGiacomo TR, et al. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J Lipid Res 1982; 23: 1224-1235.
180. Feussner G, Feussner V, Hoffmann MM, et al. Molecular basis of type III hyperlipoproteinemia in Germany. Hum Mutat 1998; 11: 417-423. doi:10.1002/(sici)1098-1004(1998)11:6<417::aid-humu1>3.0.co;2-5.
181. Civeira F, Pocovi M, Cenarro A, et al. Apo E variants in patients with type III hyperlipoproteinemia. Atherosclerosis 1996; 127: 273-282.
182. Wouters K, Shiri-Sverdlov R, van Gorp PJ, et al. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin Chem Lab Med 2005; 43: 470-479.
183. Zadelaar S, Kleemann R, Verschuren L, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007; 27: 1706-1721. doi:10.1161/atvbaha.107.142570.
184. Davignon J. Apolipoprotein E and Atherosclerosis: Beyond Lipid Effect. Arterioscler Thromb Vasc Biol 2005; 25: 267-269. DOI: 10.1161/01.ATV.0000154570.50696.2c
185. Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2005; 25: 436-441. doi:10.1161/01.atv.0000152613.83243.12.
186. Ali K, Middleton M, Puré E, et al. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res 2005; 97: 922-927. doi:10.1161/01.res.0000187467.67684.43.
187. Tenger C, Zhou X. Apolipoprotein E modulates immune activation by acting on the antigen-presenting cell. Immunology 2003; 109: 392-397. doi:10.1046/j.1365-2567.2003.01665.x.
188. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111: 1795-1803. doi:10.1172/JCI200318925.
189. Hobbs HH, Russell DW, Brown MS, et al. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990; 24: 133-170.
190. Powell-Braxton L, Veniant M, Latvala RD, et al. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med 1998; 4: 934-938.
191. Sanan DA, Newland DL, Tao R, et al. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(A). Proc Natl Acad Sci 1998; 95: 4544-4549.
192. Fenning RS, Burgert ME, Hamamdzic D, et al. Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2. J Am Heart Assoc 2015; 4. doi:10.1161/jaha.114.001477.
193. Hayashi K, Mani V, Nemade A, et al. Variations in atherosclerosis and remodeling patterns in aorta and carotids. J Cardiovasc Magn Reson 2010; 12: 10. doi:10.1186/1532-429x-12-10.
194. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, et al. Animal models of cardiovascular diseases. J Biomed Biotechnol 2011; 2011. doi:10.1155/2011/497841.
195. Moghadasian MH, McManus BM, Nguyen LB, et al. Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans. FASEB J 2001b; 15: 2623-2630. doi:10.1096/fj.01-0463com.
196. Anderson L. Laboratory Animal Medicine. Elsevier Academic Press: Oxford, 2015.
197. Skold BH, Jacobson NL, Getty R. Spontaneous atherosclerosis of bovine. J Dairy Sci 1967; 50: 1712-1714. doi:10.3168/jds.S0022-0302(67)87700-2.
198. Stout C, Bohorquez F. Aortic atherosclerosis in hoofed mammals. J Atheroscler Res 1969; 9: 73-80.
199. Gupta PP, Nagpal SK. Spontaneous aortic atherosclerosis in sheep. Vet Pathol 1979; 16: 548-552.
200. Gupta PP. Spontaneous aortic atherosclerosis in cattle. Zentralbl Veterinarmed A 1980; 27: 143-151.
201. Wiggers KD, Jacobson NL, Getty R, et al. Mode of cholesterol ingestion and atherosclerosis in young bovine. Atherosclerosis 1973; 17: 281-295. doi:10.1016/0021-9150(73)90094-4.
202. Kenealy MD, Jacobson NL, Wiggers KD. Effects of supplemental dietary cholesterol and exercise on blood cholesterol and atherosclerosis in goat. Atherosclerosis 1977; 27: 65-69. doi:10.1016/0021-9150(77)90025-9.
203. Turk JR, Laughlin MH. Physical activity and atherosclerosis: which animal model? Can J Appl Physiol-Revue Can De Physiol Appl 2004; 29: 657-683.
204. Turk JR, Henderson KK, Vanvickle GD, et al. Arterial endothelial function in a porcine model of early stage atherosclerotic vascular disease. Int J Exp Pathol 2005; 86: 335-345. doi:10.1111/j.0959-9673.2005.00446.x.
205. Simmons GH, Padilla J, Jenkins NT, et al. Exercise training and vascular cell phenotype in a swine model of familial hypercholesterolaemia: conduit arteries and veins. Exp Physiol 2014; 99: 454-465. doi:10.1113/expphysiol.2013.075838.
206. Reiser R, Sorrels MF, Williams MC. Influence of high levels of dietary fats and cholesterol on atherosclerosis and lipid distribution in swine. Circ Res 1959; 7: 833-846. doi:10.1161/01.res.7.6.833.
207. Koskinas KC, Feldman CL, Chatzizisis YS, et al. Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress a serial, in vivo intravascular ultrasound study. Circulation 2010; 121: 2092-2101.
208. Casani L, Sanchez-Gomez S, Vilahur G, et al. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost 2005; 94: 1035-1041.
209. Gal D, Chokshi S, Mosseri M, et al. Percutaneous delivery of low-level laser energy reverses histamine-induced spasm in atherosclerotic Yucatan microswine. Circulation 1992; 85: 756-768.
210. White FC, Carroll SM, Magnet A, et al. Coronary collateral development in swine after coronary artery occlusion. Circ Res 1992a; 71: 1490-1500.
211. Sturek M, Dixon JL, Stoops JD, et al. Accelerated atherosclerosis in a porcine model of diabetic dyslipidemia. Diabetes (supplement) 1998; 47 A1161.
212. Bellinger DA, Merricks EP, Nichols TC. Swine models of type 2 diabetes mellitus: insulin resistance, glucose tolerance, and cardiovascular complications. ILAR J 2006; 47: 243-258. doi:10.1093/ilar.47.3.243.
213. Ebrahim S, Papacosta O, Whincup P, et al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke 1999; 30: 841-850.
214. Cerne A, Kranjec I. Atherosclerotic burden in coronary and peripheral arteries in patients with first clinical manifestation of coronary artery disease. Heart Vessels 2002; 16: 217-226. doi:10.1007/s003800200028.
215. Lacroix P, Aboyans V, Espaliat E, et al. Carotid intima-media thickness as predictor of secondary events after coronary angioplasty. Int Angiol 2003; 22: 279-283.
216. van der Meer IM, Bots ML, Hofman A, et al. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004; 109: 1089-1094. doi:10.1161/01.CIR.0000120708.59903.1B.
217. Cheng KS, Mikhailidis DP, Hamilton G, et al. A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 2002; 54: 528-538.
218. Prescott MF, McBride C, Hasler-Rapacz J, et al. Development of complex atherosclerotic lesions in pigs with inherited hyper-LDL cholesterolemia bearing mutant alleles for apolipoprotein B. Am J Pathol 1991; 139: 139-147.
219. Prescott MF, Hasler-Rapacz J, Linden-Reed J, et al. Familial hypercholesterolemia associated with coronary atherosclerosis in swine bearing different alleles for apolipoprotein B. Ann N Y Acad Sci 1994; 748: 283-292.
220. Hasler-Rapacz J, Ellegren H, Fridolfsson AK, et al. Identification of a mutation in the low density lipoprotein receptor gene associated with recessive familial hypercholesterolemia in swine. Am J Med Genet 1998; 76: 379-386.
221. Grunwald KAA, Schueler K, Uelmen PJ, et al. Identification of a novel Arg→Cys mutation in the LDL receptor that contributes to spontaneous hypercholesterolemia in pigs. J Lipid Res 1999; 40: 475-485.
222. Agarwala A, Billheimer J, Rader DJ. Mighty minipig in fight against cardiovascular disease. Sci Transl Med 2013; 5 166fs161. doi:10.1126/scitranslmed.3005369.
223. Al-Mashhadi RH, Sørensen CB, Kragh PM, et al. Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. Sci Transl Med 2013; 5 166ra161. doi:10.1126/scitranslmed.3004853.
224. Edwards JM, Alloosh MA, Long XL, et al. Adenosine A1 receptors in neointimal hyperplasia and in-stent stenosis in Ossabaw miniature swine. CoronArtery Dis 2008; 19: 27-31. doi:10.1097/MCA.0b013e3282f262b4[doi];00019501-200802000-00005 [pii].
225. Gal D, Isner J. Atherosclerotic Yucatan microswine as a model for novel cardiovascular interventions and imaging. Swine Model Biomed Res 1992; 1: 118-140.
226. Johnson GJ, Griggs TR, Badimon L. The utility of animal models in the preclinical study of interventions to prevent human coronary artery restenosis: analysis and recommendations. On behalf of the Subcommittee on Animal, Cellular and Molecular Models of Thrombosis and Haemostasis of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 835-843.
227. Lloyd PG, Sheehy AJ, Edward JM, et al. Leukemia inhibitory factor is upregulated in stented coronary arteries of Ossabaw swine. Coron Artery Dis 2008; 19: 217-226.
228. Lowe HC, Schwartz RS, Mac Neill BD, et al. The porcine coronary model of in-stent restenosis: current status in the era of drug-eluting stents. Catheter Cardiovasc Interv 2003; 60: 515-523. doi:10.1002/ccd.10705.
229. Sturek M, Alloosh M, Wenzel J, et al. Ossabaw Island miniature swine: cardiometabolic syndrome assessment. Swine Lab: Surg, Anesth, Imaging, and Exp Tech 2007a; 2: 397-402.
230. White C, Ramee S, Banks A, et al. The Yucatan miniature swine: an atherogenic model to assess the early potency rates of an endovascular stent. Swine Model Biomed Res 1992b: 156-162.
231. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001; 50: 537-546.
232. Mansford KR, Opie L. Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet 1968; 1: 670-671.
233. Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 1970; 22: 485-518.
234. King AJF. The use of animal models in diabetes research. Br J Pharmacol 2012; 166: 877-894. doi:10.1111/j.1476-5381.2012.01911.x.
235. Kunjathoor VV, Wilson DL, LeBoeuf RC. Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 1996; 97: 1767-1773. doi:10.1172/JCI118604.
236. Otero P, Bonet B, Herrera E, et al. Development of atherosclerosis in the diabetic BALB/c mice: prevention with Vitamin E administration. Atherosclerosis 2005; 182: 259-265. doi:10.1016/j.atherosclerosis.2005.02.024.
237. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-1031. doi:10.1038/2012.
238. Calkin AC, Forbes JM, Smith CM, et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 2005; 25: 1903-1909. doi:10.1161/01.ATV.0000177813.99577.6b.
239. Zuccollo A, Shi C, Mastroianni R, et al. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 2005; 112: 3001-3008. doi:10.1161/CIRCULATIONAHA.105.581892.
240. Tse J, Martin-Mcnaulty B, Halks-Miller M, et al. Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17β-estradiol. Atherosclerosis 1999; 144: 303-313. doi:10.1016/S0021-9150(98)00325-6.
241. Reaven P, Merat S, Casanada F, et al. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 1997; 17: 2250-2256.
242. Otis CR, Wamhoff BR, Sturek M. Hyperglycemia-induced insulin resistance in diabetic dyslipidemic Yucatan swine. Comp Med 2003; 53: 53-64.
243. Dixon JL, Shen S, Vuchetich JP, et al. Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile. J Lipid Res 2002; 43: 1618-1629. doi:10.1194/jlr.M200134-JLR200.
244. Phillips JW, Barringhaus KG, Sanders JM, et al. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation 2003; 108: 1994-1999. doi:10.1161/01.cir.0000092886.52404.50.
245. Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 365-371. doi:10.1161/01.atv.21.3.365.
246. Kennedy AJ, Ellacott KLJ, King VL, et al. Mouse models of the metabolic syndrome. Dis Model Mech 2010; 3: 156-166. doi:10.1242/dmm.003467.
247. Hasty AH, Shimano H, Osuga J, et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 2001; 276: 37402-37408. doi:10.1074/jbc.M010176200.
248. Mertens A, Verhamme P, Bielicki JK, et al. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003; 107: 1640-1646. doi:10.1161/01.cir.0000056523.08033.9f.
249. Verreth W, De Keyzer D, Pelat M, et al. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 2004; 110: 3259-3269. doi:10.1161/01.cir.0000147614.85888.7a.
250. Hasty AH, Gruen ML, Terry ES, et al. Effects of vitamin E on oxidative stress and atherosclerosis in an obese hyperlipidemic mouse model. J Nutr Biochem 2007; 18: 127-133. doi:10.1016/j.jnutbio.2006.03.012.
251. Verreth W, Ganame J, Mertens A, et al. Peroxisome proliferator-activated receptor-alpha, gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice. Arterioscler Thromb Vasc Biol 2006; 26: 922-928. doi:10.1161/01.ATV.0000207318.42066.bb.
252. Gruen ML, Saraswathi V, Nuotio-Antar AM, et al. Plasma insulin levels predict atherosclerotic lesion burden in obese hyperlipidemic mice. Atherosclerosis 2006; 186: 54-64. doi:10.1016/j.atherosclerosis.2005.07.007.
253. Wu KK, Wu TJ, Chin J, et al. Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. Atherosclerosis 2005; 181: 251-259. doi:10.1016/j.atherosclerosis.2005.01.029.
254. Wendt T, Harja E, Bucciarelli L, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006; 185: 70-77. doi:10.1016/j.atherosclerosis.2005.06.013.
255. Atkinson RD, Coenen KR, Plummer MR, et al. Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice. Am J Physiol Endocrinol Metab 2008; 294: E284-E290. doi:10.1152/ajpendo.00601.2007.
256. Goldberg IJ. Why does diabetes increase atherosclerosis? I don't know!. J Clin Invest 2004; 114: 613-615. doi:10.1172/JCI200422826.
257. Martin RJ, Gobble JL, Hartsock TH, et al. Characterization of an obese syndrome in the pig. Proc Soc Exp Biol Med 1973; 143: 198-203.
258. Neeb ZP, Edwards JM, Alloosh M, et al. Metabolic syndrome and coronary artery disease in ossabaw compared with yucatan swine. Comp Med 2010; 60: 300-315.
259. 2+ entry associated with metabolic syndrome and coronary atherosclerosis. Cardiovasc Res 2010; 85: 631-640. doi:10.1093/cvr/cvp308.
260. Sturek M, Alloosh M, Wenzel J, et al. 2007b. Ossabaw Island miniature swine: cardiometabolic syndrome assessment. In Swine in the Laboratory: Surgery, Anesthesia, Imaging, and Experimental Techniques, Swindle MM (ed.). CRC Press: Boca Raton; 397-402.
261. Dyson MC, Alloosh M, Vuchetich JP, et al. Components of metabolic syndrome and coronary artery disease in female Ossabaw swine fed excess atherogenic diet. Comp Med 2006; 56: 35-45.
262. Trollope A, Moxon JV, Moran CS, et al. Animal models of abdominal aortic aneurysm and their role in furthering management of human disease. Cardiovasc Pathol 2011; 20: 114-123. doi:10.1016/j.carpath.2010.01.001.
263. Riches K, Angelini TG, Mudhar GS, et al. Exploring smooth muscle phenotype and function in a bioreactor model of abdominal aortic aneurysm. J Transl Med 2013; 11: 208. doi:10.1186/1479-5876-11-208.
264. Khan S, Verma V, Verma S, et al. Assessing the potential risk of rupture of abdominal aortic aneurysms. Clin Radiol 2015; 70: 11-20. doi:10.1016/j.crad.2014.09.016.
265. Frydman G, Walker PJ, Summers K, et al. The value of screening in siblings of patients with abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2003; 26: 396-400.
266. Nordon IM, Hinchliffe RJ, Loftus IM, et al. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol 2011; 8: 92-102. doi:10.1038/nrcardio.2010.180.
267. Klocke R, Tian W, Kuhlmann MT, et al. Surgical animal models of heart failure related to coronary heart disease. Cardiovasc Res 2007; 74: 29-38. doi:10.1016/j.cardiores.2006.11.026.
268. Townsend N, Williams J, Bhatnagar P, et al. Cardiovascular Disease Statistics 2014. British Heart Foundation: London, UK, 2014.
269. Schwartz RS, Murphy JG, Edwards WD, et al. Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries. Circulation 1990; 82: 2190-2200.
270. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992; 19: 267-274.
271. Bendixen E, Danielsen M, Larsen K, et al. Advances in porcine genomics and proteomics-a toolbox for developing the pig as a model organism for molecular biomedical research. Brief Funct Genomics 2010; 9: 208-219. doi:10.1093/bfgp/elq004.
272. Vodicka P, Smetana K, Dvoránková B, et al. The miniature pig as an animal model in biomedical research. Ann N Y Acad Sci 2005; 1049: 161-171. doi:10.1196/annals.1334.015.
273. Sanjana NE, Cong L, Zhou Y, et al. A transcription activator-like effector toolbox for genome engineering. Nat Protoc 2012; 7: 171-192. doi:10.1038/nprot.2011.431.
274. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435: 646-651. doi:10.1038/nature03556.
275. Tesson L, Usal C, Ménoret S, et al. Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol 2011; 29: 695-696. doi:10.1038/nbt.1940.
276. Carlson DF, Tan W, Lillico SG, et al. Efficient TALEN-mediated gene knockout in livestock. Proc Natl Acad Sci U S A 2012; 109: 17382-17387. doi:10.1073/pnas.1211446109.
277. Dahlem TJ, Hoshijima K, Jurynec MJ, et al. Simple methods for generating and detecting locus-specific mutations induced with TALENs in the zebrafish genome. PLoS Genet 2012; 8 e1002861. doi:10.1371/journal.pgen.1002861.
278. Lillico SG, Proudfoot C, Carlson DF, et al. Live pigs produced from genome edited zygotes. Sci Rep 2013; 3: 2847. doi:10.1038/srep02847.
279. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157: 1262-1278. doi:10.1016/j.cell.2014.05.010.
280. Ni W, Qiao J, Hu S, et al. Efficient gene knockout in goats using CRISPR/Cas9 system. PLoS One 2014; 9 e106718. doi:10.1371/journal.pone.0106718.
281. Reggio BC, James AN, Green HL, et al. Cloned transgenic offspring resulting from somatic cell nuclear transfer in the goat: oocytes derived from both follicle-stimulating hormone-stimulated and nonstimulated abattoir-derived ovaries. Biol Reprod 2001; 65: 1528-1533.
282. Hai T, Teng F, Guo R, et al. One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. Cell Res 2014; 24: 372-375. doi:10.1038/cr.2014.11.
283. Rubin CJ, Megens HJ, Martinez Barrio A, et al. Strong signatures of selection in the domestic pig genome. Proc Natl Acad Sci U S A 2012; 109: 19529-19536. doi:10.1073/pnas.1217149109.
284. Jiang Y, Xie M, Chen W, et al. The sheep genome illuminates biology of the rumen and lipid metabolism. Science 2014; 344: 1168-1173. doi:10.1126/science.1252806.
285. Hart EA, Caccamo M, Harrow JL, et al. Lessons learned from the initial sequencing of the pig genome: comparative analysis of an 8Mb region of pig chromosome 17. Genome Biol 2007; 8 R168. doi:10.1186/gb-2007-8-8-r168.
286. Rettenberger G, Klett C, Zechner U, et al. Visualization of the conservation of synteny between humans and pigs by heterologous chromosomal painting. Genomics 1995; 26: 372-378.
287. Freeman TC, Ivens A, Baillie JK, et al. A gene expression atlas of the domestic pig. BMC Biol 2012; 10: 90. doi:10.1186/1741-7007-10-90.
288. Cimini M, Boughner DR, Ronald JA, et al. Development of aortic valve sclerosis in a rabbit model of atherosclerosis: an immunohistochemical and histological study. J Heart Valve Dis 2005; 14: 365-375.
289. Nigam V, Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol 2009; 47: 828-834. doi:10.1016/j.yjmcc.2009.08.008.
290. Wada T, McKee MD, Steitz S, et al. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84: 166-178.
291. Fischer JW, Steitz SA, Johnson PY, et al. Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004; 24: 2391-2396. doi:10.1161/01.ATV.0000147029.63303.28.
292. Wachi H, Sugitani H, Murata H, et al. Tropoelastin inhibits vascular calcification via 67-kDa elastin binding protein in cultured bovine aortic smooth muscle cells. J Atheroscler Thromb 2004; 11: 159-166.